{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:23:13Z","timestamp":1791274993591,"version":"4.1.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1681\/asn.2012040367","type":"journal-article","created":{"date-parts":[[2012,8,3]],"date-time":"2012-08-03T00:06:27Z","timestamp":1343952387000},"page":"1674-1681","source":"Crossref","is-referenced-by-count":97,"title":["Folate-Conjugated Rapamycin Slows Progression of Polycystic Kidney Disease"],"prefix":"10.1681","volume":"23","author":[{"given":"Jonathan M.","family":"Shillingford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Leamon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iontcho R.","family":"Vlahov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Weimbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-14-20230208","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev.med.60.101707.125712","article-title":"Polycystic kidney disease.","volume":"60","author":"Harris","year":"2009","journal-title":"Annu Rev Med"},{"key":"R2-14-20230208","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1053\/j.ackd.2010.01.002","article-title":"Molecular advances in autosomal dominant polycystic kidney disease.","volume":"17","author":"Gallagher","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"key":"R3-14-20230208","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1073\/pnas.0509694103","article-title":"The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease.","volume":"103","author":"Shillingford","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R4-14-20230208","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1681\/ASN.2009040421","article-title":"Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1.","volume":"21","author":"Shillingford","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R5-14-20230208","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/jnci\/djm288","article-title":"Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1\/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys.","volume":"100","author":"Baba","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"R6-14-20230208","doi-asserted-by":"crossref","first-page":"e3581","DOI":"10.1371\/journal.pone.0003581","article-title":"Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia.","volume":"3","author":"Chen","year":"2008","journal-title":"PLoS ONE"},{"key":"R7-14-20230208","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1681\/ASN.2004080660","article-title":"Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease.","volume":"16","author":"Tao","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R9-14-20230208","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000104818","article-title":"Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease.","volume":"30","author":"Wu","year":"2007","journal-title":"Kidney Blood Press Res"},{"key":"R11-14-20230208","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/ki.2010.250","article-title":"Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease.","volume":"78","author":"Zafar","year":"2010","journal-title":"Kidney Int"},{"key":"R12-14-20230208","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.","volume":"363","author":"Serra","year":"2010","journal-title":"N Engl J Med"},{"key":"R13-14-20230208","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease.","volume":"363","author":"Walz","year":"2010","journal-title":"N Engl J Med"},{"key":"R14-14-20230208","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1681\/ASN.2009121302","article-title":"Sirolimus therapy to halt the progression of ADPKD.","volume":"21","author":"Perico","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R16-14-20230208","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1056\/NEJMe1006925","article-title":"mTOR inhibitors in polycystic kidney disease.","volume":"363","author":"Watnick","year":"2010","journal-title":"N Engl J Med"},{"key":"R17-14-20230208","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/ki.2010.457","article-title":"mTOR and rapamycin in the kidney: Signaling and therapeutic implications beyond immunosuppression.","volume":"79","author":"Huber","year":"2011","journal-title":"Kidney Int"},{"key":"R18-14-20230208","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.molmed.2011.06.003","article-title":"mTOR signaling in polycystic kidney disease.","volume":"17","author":"Ibraghimov-Beskrovnaya","year":"2011","journal-title":"Trends Mol Med"},{"key":"R19-14-20230208","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.transproceed.2010.07.008","article-title":"Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.","volume":"42","author":"W\u00fcthrich","year":"2010","journal-title":"Transplant Proc"},{"key":"R20-14-20230208","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/nrneph.2010.153","article-title":"Do mTOR inhibitors still have a future in ADPKD?","volume":"6","author":"Perico","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"R21-14-20230208","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1111\/j.1600-6143.2010.03152.x","article-title":"Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level?","volume":"10","author":"Canaud","year":"2010","journal-title":"Am J Transplant"},{"key":"R22-14-20230208","first-page":"1277","article-title":"Folate-targeted drug strategies for the treatment of cancer.","volume":"9","author":"Leamon","year":"2008","journal-title":"Curr Opin Investig Drugs"},{"key":"R23-14-20230208","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0083-6729(08)00407-X","article-title":"Exploitation of the folate receptor in the management of cancer and inflammatory disease.","volume":"79","author":"Leamon","year":"2008","journal-title":"Vitam Horm"},{"key":"R24-14-20230208","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1021\/bc0200430","article-title":"Synthesis and biological evaluation of EC20: A new folate-derived, (99m)Tc-based radiopharmaceutical.","volume":"13","author":"Leamon","year":"2002","journal-title":"Bioconjug Chem"},{"key":"R25-14-20230208","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ab.2004.12.026","article-title":"Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay.","volume":"338","author":"Parker","year":"2005","journal-title":"Anal Biochem"},{"key":"R26-14-20230208","first-page":"F70","article-title":"Internalization and apical-to-basolateral transport of folate in rat kidney proximal tubule.","volume":"272","author":"Birn","year":"1997","journal-title":"Am J Physiol"},{"key":"R27-14-20230208","doi-asserted-by":"crossref","first-page":"C302","DOI":"10.1152\/ajpcell.1993.264.2.C302","article-title":"Internalization and intracellular transport of folate-binding protein in rat kidney proximal tubule.","volume":"264","author":"Birn","year":"1993","journal-title":"Am J Physiol"},{"key":"R28-14-20230208","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/(SICI)1097-0215(19970422)74:2<193::AID-IJC10>3.0.CO;2-F","article-title":"Overexpression of folate binding protein in ovarian cancers.","volume":"74","author":"Toffoli","year":"1997","journal-title":"Int J Cancer"},{"key":"R29-14-20230208","first-page":"362","article-title":"Sorting of the human folate receptor in MDCK cells.","volume":"37","author":"Kim","year":"2004","journal-title":"J Biochem Mol Biol"},{"key":"R30-14-20230208","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/13861","article-title":"Mice lacking the folic acid-binding protein Folbp1 are defective in early embryonic development.","volume":"23","author":"Piedrahita","year":"1999","journal-title":"Nat Genet"},{"key":"R31-14-20230208","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1124\/mol.104.003723","article-title":"Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery.","volume":"66","author":"Paulos","year":"2004","journal-title":"Mol Pharmacol"},{"key":"R32-14-20230208","doi-asserted-by":"crossref","first-page":"e14399","DOI":"10.1371\/journal.pone.0014399","article-title":"mTORC1-S6K activation by endotoxin contributes to cytokine up-regulation and early lethality in animals.","volume":"5","author":"Lee","year":"2010","journal-title":"PLoS ONE"},{"key":"R33-14-20230208","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.2215\/CJN.01360210","article-title":"Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases.","volume":"5","author":"Torres","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R34-14-20230208","doi-asserted-by":"crossref","first-page":"re15","DOI":"10.1126\/stke.2122003re15","article-title":"TOR signaling.","volume":"2003","author":"Harris","year":"2003","journal-title":"Sci STKE"},{"key":"R35-14-20230208","doi-asserted-by":"crossref","first-page":"F693","DOI":"10.1152\/ajprenal.2001.281.4.F693","article-title":"Rapamycin impairs recovery from acute renal failure: Role of cell-cycle arrest and apoptosis of tubular cells.","volume":"281","author":"Lieberthal","year":"2001","journal-title":"Am J Physiol Renal Physiol"},{"key":"R36-14-20230208","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/00007890-199203000-00002","article-title":"The effect of rapamycin on kidney function in the Sprague-Dawley rat.","volume":"53","author":"DiJoseph","year":"1992","journal-title":"Transplantation"},{"key":"R37-14-20230208","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3109\/08923979309066932","article-title":"Functional and histopathologic effects of rapamycin on mouse kidney.","volume":"15","author":"Di Joseph","year":"1993","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"R38-14-20230208","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nature08221","article-title":"Rapamycin fed late in life extends lifespan in genetically heterogeneous mice.","volume":"460","author":"Harrison","year":"2009","journal-title":"Nature"},{"key":"R40-14-20230208","doi-asserted-by":"crossref","first-page":"R56","DOI":"10.1186\/ar3304","article-title":"Treatment of experimental adjuvant arthritis with a novel folate receptor-targeted folic acid-aminopterin conjugate.","volume":"13","author":"Lu","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"R41-14-20230208","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1016\/j.bmcl.2006.07.030","article-title":"Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide.","volume":"16","author":"Vlahov","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"key":"R42-14-20230208","doi-asserted-by":"crossref","first-page":"18067","DOI":"10.1073\/pnas.1111966108","article-title":"Signal transducer and activator of transcription-6 (STAT6) inhibition suppresses renal cyst growth in polycystic kidney disease.","volume":"108","author":"Olsan","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R43-14-20230208","doi-asserted-by":"crossref","first-page":"7985","DOI":"10.1073\/pnas.1103816108","article-title":"Polycystin-1 regulates STAT activity by a dual mechanism.","volume":"108","author":"Talbot","year":"2011","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-201210000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:21:57Z","timestamp":1786130517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-201210000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2012040367","relation":{},"ISSN":["1046-6673"],"issn-type":[{"value":"1046-6673","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}